Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O G Ottmann

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Leukemia|September 13, 2003
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemiaE Olavarria, O G Ottmann, M Deininger, et al.
Leukemia|November 15, 2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutationA A Mian, A Rafiei, I Haberbosch, et al.
Annals of Hematology|May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cellsM Bornhäuser, T Illmer, P Le Coutre, et al.
Histopathology|April 22, 2005
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Leukemia|January 11, 2012
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaH Pfeifer, T Lange, S Wystub, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparationsE Schleyer, S Pursche, C H Köhne, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Leukemia|September 13, 2003
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemiaE Olavarria, O G Ottmann, M Deininger, et al.
Leukemia|November 15, 2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutationA A Mian, A Rafiei, I Haberbosch, et al.
Annals of Hematology|May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cellsM Bornhäuser, T Illmer, P Le Coutre, et al.
Histopathology|April 22, 2005
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Leukemia|January 11, 2012
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaH Pfeifer, T Lange, S Wystub, et al.
Leukemia|December 14, 2011
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparationsE Schleyer, S Pursche, C H Köhne, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Pageof 14